Large biopharma companies cull about 40 immuno-oncology programs over the last two quarters
Clinical trial failures, patient enrollment struggles, new priorities and a transformed FDA are just a few of the reasons why some of the top biopharma companies decided to cut about 40 different immuno-oncology development programs over the last two quarters, an SVB Securities analysis shows — confirming more than a half dozen Endpoints News articles.
AstraZeneca, Bristol Myers Squibb, Roche, Janssen, Bayer, Pfizer, Gilead, AbbVie and Merck KGaA all cut 21 different IO programs linked to a variety of new and follow-on indications, according to SVB Securities’ tally for Q4.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.